Last close As at 21/08/2026
CHF139.00
— 0.00 (0.00%)
Market capitalisation
CHF273m
Research: Industrials
Orell Füssli is a diversified Swiss company operating in security printing, industrial systems, publishing, book retailing and digital identity solutions. With over 500 years of heritage, it has evolved from traditional printing to become a leading banknote printer as well as Switzerland’s leading book retailer and largest private learning content provider. The company has made significant progress towards meeting its strategic targets in recent years, and we note its potential to review targets later in the year to coincide with its capital markets day (CMD) on 11 November. We value Orell Füssli at CHF168.5/share, implying a 32% discount.
| Year end | Revenue (CHFm) | EBIT (CHFm) | PBT (CHFm) | EPS (CHF) | DPS (CHF) | P/E (x) | Yield (%) |
|---|---|---|---|---|---|---|---|
| 12/23 | 232.2 | 18.1 | 18.4 | 6.14 | 3.90 | 18.6 | 3.4 |
| 12/24 | 252.5 | 22.6 | 21.7 | 7.19 | 4.40 | 15.9 | 3.8 |
| 12/25e | 273.1 | 28.0 | 28.2 | 10.72 | 5.72 | 10.7 | 5.0 |
| 12/26e | 281.1 | 28.7 | 28.9 | 10.98 | 6.01 | 10.4 | 5.2 |
In FY24, Security Printing generated c 34% of group revenue, Book Retailing 49%, Industrial Systems 10% and Publishing and Digital combined generated 7%. The company’s most compelling growth opportunity is through Procivis, capitalising on the EU eIDAS 2.0 regulation, which was the subject of a recent positive vote in Switzerland, which requires digital wallets by 2026.
Orell Füssli delivered outstanding FY24 results and momentum continued into H125, with revenue of CHF120.1m (+12.1% y-o-y) and EBIT of CHF10.2m. Revenue expansion far exceeded the company’s organic growth target of 4–6% and demonstrated strong operational leverage (H125 vs H124). The Security Printing division won two new central bank key customers in 2024, providing multi-year contract visibility, and is operating at full capacity in 2025.
One of the company’s targets is to generate CHF300m in revenue by FY28, supported by digital and acquired revenue of CHF30–50m. It targets an EBIT margin of at least 8%. Given both the organic and acquired growth in recent periods and the fact that it exceeded the margin target in FY24 and H125, it seems likely that Orell Füssli will review these targets. It will host a CMD on 11 November in Zurich, at which the revised targets are likely to be discussed.
Orell Füssli operates under four divisions, with two stable cash-generating divisions accounting for the lion’s share of value. We have chosen to value the company on a sum-of-the-parts (SOTP) basis and on our estimates, we value Orell Füssli at CHF168.5/share, which implies that the share currently trades at a c 32% discount to our valuation.
The following factors appear to drive Orell Füssli's stock performance:
Orell Füssli has maintained steady progress across all divisions in recent months:
Founded in 1519 by Christoph Froschauer in Zurich, Orell Füssli is one of the world’s oldest continuously operating companies and Switzerland’s oldest listed company (since 1897). What began as a printing house during the Swiss Reformation has evolved into a diversified technology leader serving governments and educational institutions globally.
Orell Füssli operates through four main divisions:
The company’s competitive advantages stem from its unparalleled heritage and a reputation built over 500 years, technology leadership in security features, the credibility provided by its relationship with the Swiss National Bank, which is both a major shareholder and customer, and an integrated approach combining physical security printing with digital identity solutions. It has a resilient business model that was unaffected by recent tariff announcements and is attractive to investors as c 70% of revenue is generated in CHF. As one of the largest global independant banknote printers, Orell Füssli competes with industry leaders including De La Rue (UK), Giesecke & Devrient (Germany) and Crane Currency (US).
Despite digitalisation concerns, global banknote demand continues to grow at 4–6% annually, driven by population growth, limited banking penetration in emerging markets and central bank policies on maintaining cash as legal tender. The Swiss education market offers low but consistent growth, with government spending growth supporting publishing and book retail operations.
Through its subsidiary Procivis, Orell Füssli is pioneering the transition from physical to digital identity documents. The EU’s eIDAS 2.0 regulation is creating a mandatory market for digital identity solutions by 2026, putting Procivis in a position to leverage the parent company’s government relationships and security expertise in this emerging high-growth segment. Procivis’s software called Procivis One already meets the regulatory requirements to allow Orell to meet this new challenge.
Orell Füssli has delivered three consecutive years of strong growth and margin expansion. FY24 revenues of CHF252.5m (+8.7% y-o-y) were driven by robust performance across all divisions, with Security Printing particularly strong due to new key customers and a favourable product mix. EBIT reached CHF22.6m (+24.5% y-o-y), representing margin expansion to 8.9% from 7.8% in FY23.
The H125 results demonstrated continued momentum, with revenue of CHF120.1m (+12.1% y-o-y) and an EBIT margin of 8.5%, significantly exceeding management's 4–6% organic growth guidance. Security Printing contributed revenue of CHF47.3m (+24.7% y-o-y) while operating at full capacity and Book Retailing maintained resilience despite challenging consumer conditions.
The balance sheet remains robust, with equity to total assets ratio of 73.8% and operating cash flow generation of CHF28.2m in FY24, supporting the dividend increase to CHF4.40. The company maintains a debt-free balance sheet and therefore has financial flexibility for strategic investments while delivering progressive shareholder returns.
Management's FY28 targets of CHF300m in revenue and an EBIT margin of more than 8% appear increasingly achievable, supported by 4–6% organic growth supplemented by CHF30–50m in additional revenue from digital business development and selective acquisitions.
We have adopted an SOTP valuation approach as there is little direct relationship between the group’s two major profit centres. We arrive at a valuation of CHF168.5/share, which implies a c 32% discount to fair value.
For the two major profit contributors, Security Printing and Book Retailing, we have applied the FY25 consensus EV/operating profit ratio average of peers, which is 13.0x (ANY Biztonsági Nyomda, Crane NXT and De La Rue) and 12.7x (WHSmith) for the divisions respectively. For the smaller Industrial Systems division we have applied an EV/operating profit multiple of 8.0x being the average of two peers, and for the loss-making ‘Other businesses’ we have applied an EV/revenue multiple, again versus peers. Once we have deducted a value for the ‘not assigned’ costs, we arrive at a group value of CHF394m.
We then add the FY25 expected net cash, deduct c CHF47m for the minorities (Book Retailing is a JV) and apply a notional 20% conglomerate discount. This gives us a value of CHF330.2m, or CHF168.5 per share, compared to the current share price of CHF114.5.
Orell Füssli
Dietzingerstrasse 3
8036 Zurich
Switzerland
+41 44 466 77 11
info@orellfuessli.com
Dr Martin Folini, Chairman
Dr Folini has been a member of the board since 2020 and has held senior positions in several industrial organisations, including Isopress, Rieter, K R Pfiffner and most recently as CEO of Saurer Group. He studied at ETH Zurich and at AMP Wharton School, University of Pennsylvania.
Daniel Link, CEO
Mr Link has been CEO of Orell Füssli since 2019. Before this appointment, he held the same position at Bräker and Gebrüder Loepfe. He previously held several research and development roles at Laboratoire de Production Microtechnique, OC Oerlikon/ESEC and Rieter. He studied at the École Polytechnique Fédérale de Lausanne and has an MBA from the University of St Gallen.
Reto Janser, CFO
Mr Janser was appointed as CFO in June 2021, having held similar positions at ERNI Management Services and Suhner Holdings from 2014. Before this, he held a number of positions at Swiss Re Group, Booz Allen Hamilton, Würth Holding and Würth Finance International. He studied at the University of St Gallen.
Swiss National Bank
Dieter Meier, Zurich (held by Campdem Development)
Family of Siegert, Meerbusch
33.3
12.1
7.9
General disclaimer and copyright
This report has been commissioned by Orell Füssli and prepared and issued by Edison, in consideration of a fee payable by Orell Füssli. Edison Investment Research standard fees are £60,000 pa for the production and broad dissemination of a detailed note (Outlook) following by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.
Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the research department of Edison at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.
Exclusion of Liability: To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out or in connection with the access to, use of or reliance on any information contained on this note.
No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison’s solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.
Investment in securities mentioned: Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest.
Copyright 2025 Edison Investment Research Limited (Edison).
Australia
Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Crown Wealth Group Pty Ltd who holds an Australian Financial Services Licence (Number: 494274). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.
New Zealand
The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are “wholesale clients” for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a “personalised service” and, to the extent that it contains any financial advice, is intended only as a “class service” provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision.
United Kingdom
This document is prepared and provided by Edison for information purposes only and should not be construed as an offer or sol icitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.
This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document.
This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.
United States
Edison relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Edison does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.
London │ New York │ Frankfurt
20 Red Lion Street
London, WC1R 4PS
United Kingdom
Research: Healthcare
Percheron Therapeutics has reported final results from the Phase I dose escalation study of HMBD-002, its monoclonal antibody targeting VISTA, a novel immune checkpoint protein. The data confirmed the compound’s favourable safety and tolerability profile (maximum tolerated dose not reached with <10% of patients experiencing grade 3 or greater adverse events), with early signs of disease control in advanced solid tumours. The trial was not designed or sufficiently powered to demonstrate efficacy; however, evidence of stable disease (28% of cases) in an otherwise heavily pre-treated patient population (median four to five prior lines of treatment) supports Percheron’s move towards Phase II development in CY26. We expect the announcement on the Phase II design and target indications, due in Q4 CY25, as the next big catalyst for the company.